Evommune (EVMN) vs Cartesian Therapeutics (RNAC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Cartesian Therapeutics is the larger company by market cap ($189.7 million vs $187.6 million), about 1.0 times the size, while Evommune is growing revenue faster (+85.7% vs -92.8%). Evommune converts more of its revenue into profit, with a net margin of -529.8% versus -4658.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVMN | RNAC |
|---|---|---|
| Share price | $5.17 | $6.27 |
| Market cap | $187.63M | $189.70M |
| 1-day change | -12.82% | -4.71% |
| YTD return | -69.80% | -13.04% |
| 1-year return | — | -30.41% |
| 5-year return | — | -94.71% |
| EPS (TTM) | $-3.68 | $-5.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $13.00M | $2.80M |
| Revenue growth (YoY) | +85.71% | -92.81% |
| Net income (latest FY) | $-68.87M | $-130.30M |
| Operating margin | -623.62% | -5127.10% |
| Net margin | -529.77% | -4658.63% |
| 52-week high | $33.20 | $11.00 |
| 52-week low | $5.09 | $5.60 |
| Distance from 52-week high | -84.43% | -43.00% |
| Analyst consensus | buy | none |
| Avg. price target upside | +331.91% | +437.00% |
| Average volume | 685.46K | 131.23K |
| Shares outstanding | 36.29M | 30.26M |
| Employees | 48 | 75 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Evommune is more profitable, keeping -529.8 cents of every revenue dollar as net income versus -4658.6 cents for Cartesian Therapeutics.
- Evommune grew revenue faster in its latest fiscal year (+85.71% vs -92.81%).
About Evommune
EVMN stock →Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Cartesian Therapeutics
RNAC stock →Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
EVMN vs RNAC FAQ
Which is bigger, Evommune or Cartesian Therapeutics?
Cartesian Therapeutics (RNAC) is larger, with a market capitalization of $189.70M compared with $187.63M for Evommune (EVMN).
Are Evommune and Cartesian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.